HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mark F. O’Brien Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray, M. J. Articles by O’Brien, M. F. Search for Related Content PubMed PubMed Citation Articles by Ray, M. J. Articles by O’Brien, M. F. Related Collections Cardiac - pharmacology Extracorporeal circulation

Ann Thorac Surg 2001;71:838-843
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost

^a Department of Haematology, Queensland Health Pathology Service, Brisbane, Australia
^b Department of Cardiac Surgery, The Prince Charles Hospital, Brisbane, Australia

Accepted for publication July 29, 2000.

Address reprint requests to Dr Ray, Department of Haematology, The Prince Charles Hospital, Chermside, Brisbane, 4032, Australia
e-mail: raymj{at}health.qld.gov.au

Background. In this study we compared the clinical efficiency, safety, and economic benefit of low-dose aprotinin with epsilon aminocaproic acid (EACA) in reducing bleeding after cardiopulmonary bypass operation.

Methods. In a double-blind, randomized study, 100 patients received low-dose aprotinin (2 x 10⁶ kallikrein inhibitor units) or EACA (20 g). The surgical procedure was single- or double-valve replacement with or without coronary artery bypass grafts.

Results. Mediastinal chest drainage and transfusion requirements with both therapies were similar. There were no urgent reoperations to secure hemostasis in either group. Similar levels of D-dimer with both therapies indicate a similar inhibition of fibrinolysis. Release of troponin I was less in the low-dose aprotinin group 1 and 4 hours after bypass, although electrocardiographic measurements did not reflect this difference. Levels of S-100ß and neuron-specific enolase were similar with both therapies, confirming that there was no difference in the occurrence of any adverse neurologic events in either group.

Conclusions. Low-dose aprotinin and EACA showed similar effects on the reduction of intraoperative and postoperative bleeding. The lower cost of EACA with no change in safety outcome suggests it is the preferred treatment.

This article has been cited by other articles:

				P. Kempaiah, L. A. Danielson, M. Barry, and W. Kisiel Comparative Effects of Aprotinin and Human Recombinant R24K KD1 on Temporal Renal Function in Long-Evans Rats J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 940 - 945. [Abstract] [Full Text] [PDF]

				J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]